期刊
EXPERT REVIEW OF VACCINES
卷 21, 期 6, 页码 783-798出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2022.2059467
关键词
Delivery; DNA vaccine; HIV; SIV; therapeutic
类别
This review discusses the progress in developing therapeutic HIV DNA vaccines, focusing on delivery innovations to enhance vaccine immunogenicity. A central theme is the shift from needle injection delivery to using more sophisticated devices to target the skin and/or improve transfection efficiency.
Introduction Antiretroviral therapy (ART) reduces HIV replication to undetectable levels and prevents AIDS but cannot cure the infection and discontinuing ART results in viral rebound. Therefore, a primary goal of HIV therapeutic vaccine research is to induce potent HIV-specific immunity that could control viremia without ART, a so-called functional cure that eliminates the need for lifelong ART. DNA vaccines have several features that make them an attractive modality for an HIV therapeutic vaccine: they are easy to manufacture, induce T-cell and antibody responses without anti-vector immunity, and do not involve ex vivo manipulations of patient cells. Areas covered This review covers the progress in developing therapeutic HIV DNA vaccines, emphasizing delivery innovations to enhance vaccine immunogenicity. A central theme is a transition from needle injection delivery to the muscle toward using more sophisticated devices to target the skin and/or increasing transfection efficiency. Expert opinion There are multiple barriers to an effective therapeutic HIV DNA vaccine. While variables such as delivery, adjuvants, and immunogen design have been extensively explored, combining DNA vaccines with complementary approaches is underdeveloped. Complementary approaches include co-administration with latency reversal agents, immune checkpoint blockade, and targeting conserved fitness-constrained portions of the virus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据